David Horn, M.D., F.A.C.P., F.I.D.S.A.

Dr. Horn is currently the CEO and Founder of Mid-Atlantic BioTherapeutics, Inc., Doylestown, PA. Dr. Horn brings over 30 years of research & clinical expertise in numerous therapeutic areas. He has held senior positions at Bristol-Myers Squibb, Merck, Thomas Jefferson University, and continues to serve as a well-respected Industry Consultant. David is a board-certified physician in internal medicine and infectious diseases, and he is an expert in clinical development and medical affairs. Dr. Horn completed his fellowship training in infectious diseases at Brown University, Providence, RI. He is also a fellow of the American College of Physicians and a fellow of the Infectious Diseases Society of America. Dr. Horn has authored or co-authored over 75 peer reviewed publications concerning fungal diseases, bacterial infections, HIV infection and AIDS, tuberculosis, medical informatics, and sepsis. He also has extensive preclinical expertise and Phase 1 to 4 clinical trial experience.

Patrick Lam, Ph.D., Distinguished Professor, Baruch S. Blumberg Institute

Patrick Lam is currently a Distinguished Professor of Chemistry at Baruch S. Blumberg Institute and Adjunct Professor of Drexel University College of Medicine and President of Lam Drug Discovery Consultant, L.L.C. Dr. Lam has >30 years of medicinal chemistry and drug discovery experience. Patrick joined DuPont in 1984 and moved to Bristol-Myers Squibb Co. in 2001. He was the group leader/co-inventor responsible for the discovery of Eliquis®/Apixaban. Eliquis® is currently the top-selling small-molecule drug in the world, with around $17B annual sales. In 2015, the Eliquis discovery team received the American Chemical Society Heroes of Chemistry Award. In addition, he was one of the group leaders of FXIa. Moreover, Dr. Lam is internationally known as the co-discoverer of the powerful Chan-Lam Coupling Reaction. This is the copper-promoted coupling reaction for N/O-arylation with arylboronic acids. Note that the Chan-Lam Coupling Reaction to form a C-Heteoatom bond is complementary to the 2010 Nobel-prize winning Suzuki-Miyaura Coupling Reaction that makes a C-C bond. In addition, Patrick is responsible for a total of eight clinical candidates. Patrick has authored/co-authored 106 papers/reviews/book chapters and is an inventor on 38 patents/patent applications. He has presented >100 invited seminars worldwide. Patrick has received numerous awards including the BMS Ondetti-Cushman Innovation Award for FXa inhibitor discovery in 2003 and the DuPont-Merck Summit Award for the discovery of cyclic ureas as HIV protease inhibitor capable of displacing the “structured water” in 1993.

Patrick received his Ph.D. from the University of Rochester (Dr. Louis Friedrich) in 1980 and was a postdoctoral fellow in UCLA (Prof. Mike Jung and the late Prof. Don Cram, 1987 Nobel Laureate in chemistry) in 1980-1984.

Kunwar Shailubhai, Ph.D., MBA

Dr. Shailubhai is currently the CEO and Founder of Nous Biosciences, Inc. This is his third biotechnology start-up at the Pennsylvania Biotechnology Center (PABC), Doylestown, PA. Dr. Shailubhai is an experienced executive and a scientist with a demonstrated history of ‘Bench to Market’ and advancing two start-up biotechnology companies to NASDAQ listing. He has served on boards of publicly listed biotechnology companies. He has been very successful in financing, IPO processes and advancing drugs from preclinical discovery, non-clinical and clinical development to eventual FDA approval. Dr. Shailubhai has pioneered therapeutic applications of Guanylate cyclase-C and is the chief architect of the patent portfolio of Synergy Pharmaceuticals (NASDAQ: SGYP) and Tiziana Life Sciences (NASDAQ: TLSA) with 50+ world-wide issued patents and patent applications. He is the major inventor of the FDA approved drug TRULANCE and Dolcanatide, a drug candidate in phase 2 clinical evaluation. Moreover, he has developed and patented novel technologies for alternative routes of immuno-therapeutics for gastrointestinal, lung and neurodegenerative diseases. Dr. Shailubhai has over 35 years of experience in pharma/biotech companies with increasing leadership positions and has demonstrated excellent scientific credentials that are complemented with over 20 years of executive management in pharma/biotech Companies. His therapeutic areas of interest include inflammation, autoimmune diseases, oncology and infectious diseases.

William Kim, Ph.D., Chairman, Department of Biotechnology, Suwon University

Professor Kim is the Chairman of the Biotechnology Department, Suwon University, Korea. Professor Kim has also served as an Assistant Professor at Columbia University in New York, a postdoctoral fellow at Harvard University, and he has received his Ph.D. at New York University, NY, M.Phil. at Cambridge University, UK and B.S. at Seoul National University, Korea. Professor Kim has authored numerous publications on topics including dermatology, oncology, reverse aging and cardiovascular diabetic complications with governmental and commercial funding. Professor Kim was born in New York, educated in the US, UK, and Korea, and he has spent over 30 years performing research and consultancy, and received the National Institute of Health NRSA and the American Diabetes Association faculty awards. Moreover, Professor Kim enjoys multicultural environments and shares his time between his New Jersey home and a prestigious academic campus in Korea.